Those agencies have become heavily bureaucratic coupled with the influence of big pharma and politics pushing them beyond their original purpose. They are lethargic and add to the cost innovation. But also it can be a double edged sword in that if a drug or procedure is used in the market and down the road has serious complications people demand regulatory oversight which leads back to where we are today.
Speaking of “innovation”:
FDA approves obesity drug that helped people cut weight 15%
https://medicalxpress.com/news/2021-06-fda-obesity-drug-people-weight.html
Excerpt:
Regulators on Friday said a new version of a popular diabetes medicine could be sold as a weight-loss drug in the U.S.
The Food and Drug Administration approved Wegovy, a higher-dose version of Novo Nordisk’s diabetes drug semaglutide, for long-term weight management.
In company-funded studies, participants taking Wegovy had average weight loss of 15%, about 34 pounds (15.3 kilograms). Participants lost weight steadily for 14 months before plateauing. In a comparison group getting dummy shots, the average weight loss was about 2.5%, or just under 6 pounds.
...In the U.S., more than 100 million adults—about 1 in 3—are obese.
Dropping even 5% of one’s weight can bring health benefits, such as improved energy, blood pressure, blood sugar and cholesterol levels, but that amount often doesn’t satisfy patients who are focused on weight loss...
America First Legal Scores Victory, Biden Administration Cancels Race-Based COVID Relief Fund
DOJ lawyers tell federal court that the Biden Administration has ceased its illegal processing regime and will consider applications on a race neutral, first-come-first-served basis
The tide is turning. Republicans flipped democratic mayorship in the border town of McAllen, Texas.